50 Participants Needed

Exercise for Marfan Syndrome

SA
JB
Overseen ByJennifer Bogardus, PT, MPT, PhD
Age: < 65
Sex: Any
Trial Phase: Academic
Sponsor: Baylor College of Medicine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

Marfan syndrome (MFS) is a distinctive connective tissue disorder that affects multiple organ systems including the heart, bones, ligaments, and eyes, and is associated with significant risk of aortic dissection. Given limited evidence from in-vitro studies, and theoretical concerns, the majority of patients with MFS are restricted from certain physical activities. The lack of exercise and deconditioning have detrimental effects including increasing weakness, joint pain, decreased endurance, and depressive symptoms. Given the significant paucity of data currently existing on the effects of exercise in humans with MFS, and the recent, optimistic findings in rodent models, this pilot trial was established to assess the effects of moderated dynamic exercise in adolescents and young adults with MFS.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of this treatment for Marfan Syndrome?

Research shows that a personalized home-based exercise program improved quality of life, fitness, and muscle power in Marfan Syndrome patients. Additionally, a study found that a simple physical activity intervention could slow the rate of aortic root dilation in pediatric patients with Marfan Syndrome.12345

Is exercise safe for people with Marfan syndrome?

Recent studies suggest that low to moderate intensity exercise is generally safe for people with Marfan syndrome, and there is no evidence that it worsens symptoms or increases mortality. However, it's important to follow specific guidelines and consult with healthcare providers before starting any exercise program.12456

How does the exercise treatment for Marfan Syndrome differ from other treatments?

The exercise treatment for Marfan Syndrome is unique because it involves moderate dynamic exercise, which is generally discouraged for Marfan patients due to concerns about heart and blood vessel issues. However, recent studies suggest that moderate exercise can improve heart health and reduce aortic dilation, offering a new way to manage the condition without medication.12467

Research Team

SA

Shaine A Morris, MD, MPH

Principal Investigator

Baylor College of Medicine

Eligibility Criteria

This trial is for young individuals aged 10-25 with Marfan syndrome, which affects the body's connective tissue. Participants must meet specific diagnostic criteria and cannot have had aortic or spinal surgery, major heart defects (except some conditions like mitral valve prolapse), conditions that limit moderate exercise, or an aorta wider than 4.5 cm.

Inclusion Criteria

I am between 10 and 25 years old.
I have been diagnosed with Marfan syndrome.

Exclusion Criteria

I have had surgery on my aorta.
I do not have any major health issues that could affect the study's results.
My aorta is enlarged to 4.5 cm or more, needing surgery.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Participants undergo preliminary outcome measure testing including cardiovascular, musculoskeletal, and psychological screening

1-2 weeks

Treatment

Participants in the exercise intervention group receive education, demonstration, and follow-up on moderate dynamic exercise

16 weeks
Regular follow-up visits to ensure compliance and safety

Follow-up

Participants are monitored for safety and effectiveness after treatment, including reassessment of all baseline procedures

4 weeks

Treatment Details

Interventions

  • Control Group
  • Exercise Intervention Group
Trial OverviewThe study examines how safe and effective moderated dynamic exercise is for adolescents and young adults with Marfan Syndrome. It compares an exercise intervention group to a control group that does not receive this intervention.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Exercise Intervention GroupExperimental Treatment1 Intervention
Group of up to 50 patients will randomly allocated into an experimental group at a 4:1 ratio intervention to controls. The experimental group will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening) in addition to exercise intervention education, demonstration, and follow up to ensure compliance and safety.
Group II: Control GroupExperimental Treatment1 Intervention
Control group will be randomly allocated at a 4:1 ratio, intervention to controls.. The control group will receive all of the preliminary outcome measure testing (cardiovascular, musculoskeletal, and psychological screening) and will be instructed to continue with baseline physical activities. They will be asked to return for a reassessment of all baseline procedures (cardiovascular, musculoskeletal, and psychological screening).

Find a Clinic Near You

Who Is Running the Clinical Trial?

Baylor College of Medicine

Lead Sponsor

Trials
1,044
Recruited
6,031,000+

Southern Star Research Pty Ltd.

Industry Sponsor

Trials
14
Recruited
620+

Southern Star Research

Industry Sponsor

Trials
14
Recruited
630+

Findings from Research

A 3-month personalized home-based training program for patients with Marfan syndrome (MFS) showed a significant improvement of 50% in quality of life, cardiorespiratory fitness, and skeletal muscle power for those who completed the combined training.
The study involved at least 50 MFS patients who participated in telemonitored training sessions, suggesting that structured physical activity can be a beneficial alternative for managing MFS and enhancing patient well-being.
Effects of a personalized home-based training program among patients suffering from Marfan syndrome: a pilot randomized and controlled study.Jouini, S., Milleron, O., Eliahou, L., et al.[2021]
Recent recommendations suggest that low-intensity physical activity (PA) can be beneficial for patients with Marfan syndrome (MFS), despite previous guidelines advising against exercise.
While moderate aerobic or weight training does not appear to worsen symptoms or increase mortality in MFS patients, high-intensity exercise (75-85% of maximal oxygen uptake) may have harmful effects, although this has primarily been observed in animal studies.
Is physical activity a future therapy for patients with Marfan syndrome?Jouini, S., Milleron, O., Eliahou, L., et al.[2022]
Subjects with Marfan syndrome showed increased lung volumes but reduced peak oxygen uptake compared to healthy individuals, indicating compromised pulmonary function despite larger lung capacity.
Most participants could complete a maximal exercise test without serious complications, but their reduced aerobic capacity suggests a need for tailored exercise guidelines to improve fitness and monitor changes with age.
Pulmonary function, working capacity and strength in young adults with Marfan syndrome.Giske, L., Stanghelle, JK., Rand-Hendrikssen, S., et al.[2019]

References

Effects of a personalized home-based training program among patients suffering from Marfan syndrome: a pilot randomized and controlled study. [2021]
Is physical activity a future therapy for patients with Marfan syndrome? [2022]
Pulmonary function, working capacity and strength in young adults with Marfan syndrome. [2019]
Can 10 000 Healthy Steps a Day Slow Aortic Root Dilation in Pediatric Patients With Marfan Syndrome? [2023]
Inpatient rehabilitation for adult patients with Marfan syndrome: an observational pilot study. [2018]
Cardiovascular Benefits of Moderate Exercise Training in Marfan Syndrome: Insights From an Animal Model. [2022]
Mild aerobic exercise blocks elastin fiber fragmentation and aortic dilatation in a mouse model of Marfan syndrome associated aortic aneurysm. [2018]